PACT Pharma is dedicated to synthesizing a tsunami of neo-epitope targeted T cells and producing a personalized adoptive cell therapy designed to benefit each individual cancer patient. Founded by Antoni Ribas, David Baltimore, and Jim Heath in 2016, PACT Pharma is backed by investors that include Canaan Partners, UpHonest Capital, GV, Casdin Capital, and Invus and is headquartered in Hayward.